Want to see HK:3613 full AI Analyst Report?
Top Page
Beijing Tong Ren Tang Chinese Medicine Co
(3613)
Select Model
Select Model
Rating:72Outperform
Price Target:
HK$6.50
â–¼(-0.61% Downside)
Action:Reiterated
Date:09/09/26
The score is driven primarily by strong financial quality (high margins, low leverage, and solid TTM rebound) and supportive valuation (P/E ~10.9 and ~6.19% dividend yield). These positives are tempered by clearly bearish technicals (price below all key moving averages and negative MACD), which meaningfully lowers the overall score.
Positive Factors
High Profitability
The company’s high gross and net margins indicate substantial earnings capacity from its TCM portfolio and brand-led sales model. Strong profitability can support product investment, distribution development, and resilience over the next several quarters, provided margins remain defensible.
Negative Factors
Uneven Revenue Growth
The recent rebound is encouraging, but declines in multiple annual periods show that top-line expansion has not been consistently steady. Uneven revenue performance can make channel planning and operating leverage less predictable, increasing reliance on continued recovery in demand.
Read all positive and negative factors
Positive Factors
Negative Factors
High Profitability
The company’s high gross and net margins indicate substantial earnings capacity from its TCM portfolio and brand-led sales model. Strong profitability can support product investment, distribution development, and resilience over the next several quarters, provided margins remain defensible.
Read all positive factors
Beijing Tong Ren Tang Chinese Medicine Co (3613) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$4.73B
Dividend Yield6.68%
Average Volume (3M)1.21M
Price to Earnings (P/E)10.2
Beta (1Y)0.45
Revenue Growth-20.79%
EPS Growth-30.04%
CountryHK
Employees763
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.55
Shares Outstanding837,100,000
10 Day Avg. Volume814,345
30 Day Avg. Volume1,213,931
Financial Highlights & Ratios
PEG Ratio-0.83
Price to Book (P/B)1.69
Price to Sales (P/S)4.68
P/FCF Ratio8.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.50Price Target Upside60.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.53
Revenue Forecast (FY)HK$1.49B
Beijing Tong Ren Tang Chinese Medicine Co Business Overview & Revenue Model
Company Description
Beijing Tong Ren Tang Chinese Medicine Company Limited, encompassing its various affiliates, specializes in the production, distribution, and direct sale of traditional Chinese medicine and wellness items, catering to both corporate distributors a...
How the Company Makes Money
The company primarily makes money by selling TCM products through a combination of wholesale/distribution and direct retail. Revenue is generated from (1) sales of proprietary Chinese medicines and other branded TCM/health products to distributors...
Beijing Tong Ren Tang Chinese Medicine Co Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
91
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.65B | 1.51B | 1.61B | 1.52B | 1.73B | 1.56B |
| Gross Profit | 1.04B | 925.58M | 1.07B | 1.05B | 1.15B | 1.12B |
| EBITDA | 684.33M | 574.36M | 722.32M | 779.54M | 907.63M | 852.81M |
| Net Income | 459.65M | 397.22M | 500.28M | 540.39M | 645.88M | 607.84M |
Balance Sheet | ||||||
| Total Assets | 4.51B | 4.66B | 4.56B | 4.43B | 4.23B | 3.83B |
| Cash, Cash Equivalents and Short-Term Investments | 2.21B | 2.28B | 1.82B | 2.38B | 2.24B | 2.28B |
| Total Debt | 125.80M | 126.54M | 123.42M | 131.81M | 103.08M | 128.48M |
| Total Liabilities | 272.67M | 291.88M | 313.09M | 413.75M | 486.49M | 295.48M |
| Stockholders Equity | 4.05B | 4.19B | 4.08B | 3.87B | 3.60B | 3.42B |
Cash Flow | ||||||
| Free Cash Flow | 928.86M | 827.05M | -260.42M | 438.96M | 508.94M | 753.74M |
| Operating Cash Flow | 969.98M | 868.23M | -217.25M | 460.83M | 547.44M | 777.17M |
| Investing Cash Flow | 230.23M | -37.73M | 1.35B | -1.08B | 335.41M | -265.73M |
| Financing Cash Flow | -645.15M | -381.05M | -355.30M | -372.18M | -535.42M | -278.65M |
Beijing Tong Ren Tang Chinese Medicine Co Technical Analysis
Neutral
6.54
Price Trends
5.80
Negative
6.22
Negative
6.90
Negative
Market Momentum
-0.04
Negative
48.56
Neutral
22.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:3613, the sentiment is Neutral. The current price of 6.54 is above the 20-day moving average (MA) of 5.61, above the 50-day MA of 5.80, and below the 200-day MA of 6.90, indicating a neutral trend. The MACD of -0.04 indicates Negative momentum. The RSI at 48.56 is Neutral, neither overbought nor oversold. The STOCH value of 22.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:3613.
Beijing Tong Ren Tang Chinese Medicine Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$6.56B | 13.02 | 20.84% | 6.55% | 11.78% | 34.19% | |
72 Outperform | HK$4.73B | 10.23 | 11.15% | 6.68% | -20.79% | -30.04% | |
64 Neutral | HK$3.82B | 10.78 | 4.19% | 6.93% | -13.93% | -25.30% | |
56 Neutral | HK$8.28B | 37.23 | 4.32% | 3.22% | -0.52% | -37.60% | |
53 Neutral | HK$5.89B | -4.81 | -4.98% | 0.31% | -15.80% | -298.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$237.60M | -4.64 | -8.62% | 2.98% | 2.06% | -298.25% |
* Healthcare Sector Average
HK:3613
Beijing Tong Ren Tang Chinese Medicine Co
5.65
-2.49
-30.59%
HK:0570
China Traditional Chinese Medicine Holdings Co
1.17
-1.17
-50.00%
HK:1666
Tong Ren Tang Technologies Co
2.99
-1.39
-31.69%
HK:1643
Modern Chinese Medicine Group Co. Ltd.
0.33
-0.41
-55.41%
HK:2273
Gushengtang Holdings Limited
28.08
1.42
5.34%
HK:0719
Shandong Xinhua Pharmaceutical Company Limited Class H
5.35
-1.40
-20.71%
Beijing Tong Ren Tang Chinese Medicine Co Corporate Events
Beijing Tong Ren Tang Chinese Medicine Publishes 2026 Interim Results Announcement
Aug 28, 2026
Beijing Tong Ren Tang Chinese Medicine Company Limited has released its unaudited interim results for the six months ended 30 June 2026, meeting disclosure requirements of the Hong Kong listing rules. The full interim report will be available in p...
Beijing Tong Ren Tang Chinese Medicine Signs Connected E-commerce Services Deal
Aug 28, 2026
Beijing Tong Ren Tang Chinese Medicine has signed an E-commerce Services Cooperation Framework Agreement with Tong Ren Tang Shuzi Technology under which the latter will provide e-commerce operation services for Tong Ren Tang–branded products...
Beijing Tong Ren Tang Chinese Medicine Wins Hong Kong Approval for New Proprietary Remedy
Aug 28, 2026
Beijing Tong Ren Tang Chinese Medicine Company Limited has obtained a Certificate of Registration of Proprietary Chinese Medicine in Hong Kong for its Sanzi Yangqin Keli product, allowing the granule formulation to be sold in the city until August...
Beijing Tong Ren Tang Chinese Medicine Sets Board Meeting to Approve Interim Results and Consider Dividend
Aug 14, 2026
Beijing Tong Ren Tang Chinese Medicine Company Limited has scheduled a board meeting for 28 August 2026 in Hong Kong. The directors will review and approve the interim results for the six months ended 30 June 2026 and consider whether to declare a...
Beijing Tong Ren Tang Chinese Medicine Shifts to New Product Sales Framework with Controlling Shareholder
Jun 29, 2026
Beijing Tong Ren Tang Chinese Medicine Company Limited has overhauled its transaction framework with controlling shareholder Tong Ren Tang Technologies, shifting from a distribution-focused model in mainland China to a procurement-driven arrangeme...
Beijing Tong Ren Tang Chinese Medicine Wins Strong Shareholder Backing at AGM
Jun 10, 2026
Beijing Tong Ren Tang Chinese Medicine Company Limited reported that all ordinary resolutions at its 10 June 2026 annual general meeting were duly passed, with shareholders representing 619,946,650 shares voting. The meeting approved the 2025 audi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.